United Therapeutics (UTHR) Receives “Underperform” Rating from Credit Suisse Group

United Therapeutics (NASDAQ:UTHR)‘s stock had its “underperform” rating reiterated by equities researchers at Credit Suisse Group in a research note issued on Thursday. They presently have a $118.00 price objective on the biotechnology company’s stock. Credit Suisse Group’s price target indicates a potential downside of 15.42% from the stock’s previous close.

A number of other research analysts have also recently issued reports on UTHR. ValuEngine raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Tuesday, December 26th. BidaskClub raised United Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, December 6th. Zacks Investment Research raised United Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, October 9th. Wedbush reaffirmed an “outperform” rating and issued a $232.00 price target (up from $213.00) on shares of United Therapeutics in a report on Wednesday, December 27th. Finally, Cowen reaffirmed a “hold” rating and issued a $129.00 price target on shares of United Therapeutics in a report on Friday, October 27th. Four analysts have rated the stock with a sell rating, five have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $140.27.

Shares of United Therapeutics (NASDAQ:UTHR) traded down $0.02 during midday trading on Thursday, hitting $139.51. The company’s stock had a trading volume of 425,793 shares, compared to its average volume of 360,801. The company has a market capitalization of $6,028.37, a PE ratio of 12.30 and a beta of 1.41. United Therapeutics has a 12 month low of $112.01 and a 12 month high of $169.89.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $4.01 by $2.26. The company had revenue of $445.50 million during the quarter, compared to analysts’ expectations of $426.43 million. United Therapeutics had a return on equity of 26.24% and a net margin of 30.50%. The business’s revenue was up 9.1% on a year-over-year basis. During the same period last year, the business earned $4.23 earnings per share. analysts predict that United Therapeutics will post 12.96 earnings per share for the current fiscal year.

In related news, CEO Martine A. Rothblatt sold 1,241 shares of United Therapeutics stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $128.95, for a total value of $160,026.95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Christopher Causey sold 580 shares of United Therapeutics stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $122.00, for a total value of $70,760.00. Following the completion of the sale, the director now owns 2,135 shares of the company’s stock, valued at $260,470. The disclosure for this sale can be found here. Over the last quarter, insiders sold 14,508 shares of company stock valued at $1,774,621. Corporate insiders own 7.80% of the company’s stock.

Several institutional investors have recently bought and sold shares of UTHR. Quantbot Technologies LP grew its position in shares of United Therapeutics by 537.3% during the 3rd quarter. Quantbot Technologies LP now owns 975 shares of the biotechnology company’s stock worth $114,000 after buying an additional 822 shares during the period. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of United Therapeutics during the 3rd quarter worth about $156,000. Toronto Dominion Bank grew its position in shares of United Therapeutics by 244.7% during the 3rd quarter. Toronto Dominion Bank now owns 1,903 shares of the biotechnology company’s stock worth $223,000 after buying an additional 1,351 shares during the period. Meiji Yasuda Asset Management Co Ltd. acquired a new position in shares of United Therapeutics during the 3rd quarter worth about $233,000. Finally, TLP Group LLC acquired a new position in shares of United Therapeutics during the 2nd quarter worth about $246,000.

TRADEMARK VIOLATION WARNING: “United Therapeutics (UTHR) Receives “Underperform” Rating from Credit Suisse Group” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.americanbankingnews.com/2018/01/21/united-therapeutics-uthr-receives-underperform-rating-from-credit-suisse-group.html.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply